微信小陈
微信小章| 产品名称： | LS132.8G2 8G2 |
|---|---|
| 商品货号： | TS164514 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Tissue： | spleen |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Lymphoma |
| Strain： | Strain:xa0 C57BL/6xa0 (B cell); BALB/cxa0 (myeloma) |
| Applications： | The antibody binds to the human CC-chemokine receptor 2 (CCR2). Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images： |  |
| Derivation： | Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2). |
| Comments： | Animals were immunized with CCR2bDEF3.L1/2 cells derived from the murine pre-B lymphoma cell line, L1/2, transfected with the human CCR2B cDNA coding region. Spleen cells were fused Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 2 (CCR2). |
| Complete Growth Medium： | Dulbeccos modified Eagles medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 25 mM HEPES, 20 pg/ml mouse recombinant Interleukin-6 (IL-6) and 20% fetal bovine serum
|
| Subculturing： | Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation and subsequent resuspension at 1 x 10(5) viable cells/ml. Interval: Maintain cell concentration between 1.0 x 10(5) and 1.0 x 10(6) cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype： | IgM kappa |
| Name of Depositor： | LeukoSite, Inc. |
| U.S. Patent Number： | |
| References： | LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,312,689 dated Nov 6 2001 LaRosa GJ, et al. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,352,832 dated Mar 5 2002 LaRosa GJ. Method of inhibiting leukocyte trafficking by anti-CCR2 amino-terminal domain antibodies. US Patent 6,395,497 dated May 28 2002 LaRosa GJ. Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies. US Patent 6,406,865 dated Jun 18 2002 LaRosa GJ. Anti-CCR2 antibodies. US Patent 6,406,694 dated Jun 18 2002 LaRosa GJ. Method of inhibiting cell function associated with CCR2 by anti-CCR2 amino-terminal domain antibodies. US Patent 6,448,021 dated Sep 10 2002 LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,451,522 dated Sep 17 2002 . Anti-CCR2 antibodies and methods of use therefor. US Patent 6,458,353 dated Oct 1 2002 LaRosa GJ. Anti-CCR2 antibodies and methods of use therefor. US Patent 6,491,915 dated Dec 10 2002 |